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Abstract
Objectives: Bioreactor‐based	 production	 systems	 have	 the	 potential	 to	 overcome	
limitations associated with conventional tissue engineering manufacturing methods, 
facilitating	regulatory	compliant	and	cost‐effective	production	of	engineered	grafts	
for	widespread	clinical	use.	In	this	work,	we	established	a	bioreactor‐based	manufac‐
turing system for the production of cartilage grafts.
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1  | INTRODUC TION
In a recent phase I clinical trial, we aimed to treat articular cartilage 
defects with cartilage tissue grafts, which were engineered from nasal 
cartilage chondrocytes.1 Given the highly promising clinical data that 
we	acquired	in	that	study,	we	now	aim	to	address	critical	manufac‐
turing related issues, which could ultimately impede the translation 
of this therapy into widespread clinical use. Since the cartilage grafts 
in our study were produced by conventional manual tissue engineer‐
ing	methods,	 the	 production	 process	was	 lengthy,	 labour‐intensive	
and	 would	 possess	 inherent	 variability	 among	 operators	 Figure	 1.	
A	manufacturing	 system	based	on	 these	manual	processes	may	be	
challenging	to	standardize,	thus	presenting	obstacles	towards	regu‐
latory compliance, and may ultimately incur high operating costs and 
challenges for upscaling, thus presenting significant barriers towards 
economic	viability.	Alternatively,	automated	bioreactor‐based	manu‐
facturing systems have the potential to overcome these limitations, 
breaking	 down	 regulatory	 and	 economic	 barriers,	 allowing	 engi‐
neered tissue therapies to reach their full clinical potential2	Figure	1.
We	have	previously	demonstrated	that	bioreactor‐based	perfu‐
sion of a cell suspension directly through the pores of a 3D scaffold 
enhances the cell seeding efficiency and cell distribution compared 
Materials & Methods: All	bioprocesses,	from	cartilage	biopsy	digestion	through	the	
generation	 of	 engineered	 grafts,	 were	 performed	 in	 our	 bioreactor‐based	 manu‐
facturing	 system.	All	 bioreactor	 technologies	 and	 cartilage	 tissue	 engineering	 bio‐
processes	were	transferred	to	an	independent	GMP	facility,	where	engineered	grafts	
were manufactured for two large animal studies.
Results: The results of these studies demonstrate the safety and feasibility of the 
bioreactor‐based	manufacturing	approach.	Moreover,	grafts	produced	in	the	manu‐
facturing system were first shown to accelerate the repair of acute osteochondral 
defects,	compared	to	cell‐free	scaffold	implants.	We	then	demonstrated	that	grafts	
produced in the system also facilitated faster repair in a more clinically relevant 
chronic	defect	model.	Our	data	also	suggested	that	bioreactor‐manufactured	grafts	
may result in a more robust repair in the longer term.
Conclusion: By	demonstrating	the	safety	and	efficacy	of	bioreactor‐generated	grafts	
in	two	large	animal	models,	this	work	represents	a	pivotal	step	towards	implementing	
the	bioreactor‐based	manufacturing	 system	 for	 the	production	of	human	cartilage	
grafts for clinical applications.
Read the Edito rial for this artic le on doi:10.1111/cpr.12625 
F I G U R E  1  Conventional	manufacturing	processes	used	to	produce	the	engineered	grafts	are	based	on	traditional	bench‐top	manual	
culture	methods.	These	manual	procedures	require	a	large	number	of	labour‐intensive	manipulations	that	pose	challenges	towards	regulatory	
compliance	and	ultimately	result	in	high	manufacturing	costs	in	the	long	term.	As	an	alternative,	bioreactor‐based	production	systems,	which	
automate and control the bioprocesses, have the potential to overcome the limitations associated with conventional manufacturing methods, 
facilitating	regulatory	compliant	and	cost‐effective	production	of	engineered	cartilage	grafts	for	widespread	clinical	use
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to conventional manual methods.3 We then demonstrated that cul‐
turing	 cell‐seeded	 constructs	 under	 perfusion	 supported	 the	 de‐
velopment of a viable and uniform tissue graft during prolonged 
culture.4	 Chemo‐optic	microsensors	were	 also	 integrated	 into	 the	
bioreactor for continuous online measurements of oxygen levels in 
the perfused culture medium. With the prospect of clinical applica‐
tions, we also upscaled the perfusion bioreactor system in order to 
engineer	clinically	 relevant,	 large‐scale	cartilage	grafts	suitable	 for	
treating	 lesions	 in	 a	human	knee.5	After	establishing	 these	 funda‐
mental	building	blocks	for	a	bioreactor‐based	production	system,	we	
then established an innovative and streamlined approach to engi‐
neer human cartilage grafts within a single bioreactor unit, from the 
introduction of primary chondrocytes freshly isolated from a biopsy, 
through the generation of a mature cartilaginous tissue graft.6
In	 this	 work,	 we	 have	 adapted	 and	 integrated	 our	 previously	
described bioreactor technologies and bioprocesses in order to es‐
tablish an automated manufacturing platform for the production 
of	 nasal	 chondrocyte‐based	 engineered	 grafts.	 Cartilage	 grafts	
were	manufactured	in	the	bioreactor‐based	system	at	a	centralized	
GMP	facility	and	were	first	assessed	in	a	 large	animal	study	based	
on	an	acute	osteochondral	defect	in	sheep.	Following	the	promising	
results from the acute defect study, we next assessed grafts gen‐
erated in our manufacturing system in a more challenging and clin‐
ically	relevant	chronic	defect	sheep	model.	The	results	of	this	work	
represent	a	pivotal	step	towards	implementing	the	bioreactor‐based	
manufacturing system for the production of human cartilage grafts 
for clinical applications.
2  | MATERIAL AND METHODS
2.1 | Scaffold preparation
The bilayered biomimetic osteochondral scaffold used in these 
studies	(Fin‐Ceramica	Faenza	SpA)	had	a	cylindrical	shape,	25	mm	
F I G U R E  2  A,	Cartilage	digestion	bioreactor.	An	automated	tissue	digest	protocol	was	developed	and	converted	to	an	automated	
algorithm	using	application‐specific	Octane	software.	The	control	system	operates	a	series	of	valve	actuators	to	open	and	close	valves	on	
the	bioreactor	cassette	and	a	peristaltic	pump	to	deliver	fluids	at	a	range	of	flow	rates.	All	biological	processes	are	housed	within	a	single	
disposable	cassette.	Automated	protocol	steps	included	(a)	tissue	washed	with	phosphate‐buffered	saline;	(b)	delivery	and	perfusion	of	
digestion	enzyme;	(c)	removal	of	the	digestion	enzyme	and	replacement	with	complete	medium;	and	(d)	cell	collection.	B,	T‐CUP	perfusion	
bioreactor.	Cell	seeding,	3D	expansion	and	differentiation	were	performed	in	a	single	perfusion	bioreactor	manufacturing	module.	Culture	
medium	is	forced	back	and	forth	between	the	inner	chamber	and	an	outer	chamber	of	the	vessel	and,	therefore,	is	perfused	directly	
through	the	3D	construct.	C,	Oxygen	and	D,	pH	sensor	data	monitored	throughout	5‐week	culture	period	in	the	T‐CUP	bioreactor.	Spikes	
in	the	oxygen	plot	are	artefacts	due	to	the	opening	of	the	incubator	door.	Peaks	in	the	pH	plot	are	due	to	fluctuations	in	pH	between	the	
introduction	of	fresh	medium	(pH	≈	7.6)	until	the	next	medium	exchange	(pH	≈	6.8‐7.0)
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in	diameter	and	5	mm	in	thickness	for	bioreactor‐generated	cell‐
based	grafts	and	a	6	mm	diameter	for	cell‐free	scaffold	implants.	
The	 top	 layer	 of	 the	 scaffold	 (3	 mm	 in	 thickness)	 consisted	 of	
equine	type	I	collagen,	and	the	bottom	layer	 (2	mm	in	thickness)	
was	made	of	 a	mineralized	blend	of	 type	 I	 collagen	and	Mg‐HA,	
mimicking	 the	 structure	 and	 biochemistry	 of	 cartilage	 and	 sub‐
chondral bone.7,8	 The	 scaffold	 was	 developed	 through	 a	 bio‐in‐
spired process, as previously described.9
2.2 | Bioreactor‐based manufacturing
The	 bioreactor‐based	manufacturing	 process	 is	 comprised	 of	 four	
main phases:
• Cartilage tissue digestion phase, in which the cartilage biopsy is 
enzymatically	digested	to	liberate	isolated	chondrocytes	in	a	cell	
suspension.
• Cell seeding phase, in which isolated primary chondrocytes are 
efficiently and uniformly seeded throughout the volume of the 
scaffold.
• 3D proliferation phase, in which chondrocytes are extensively ex‐
panded	in	number	to	colonize	the	volume	of	the	scaffold.
• Differentiation phase, in which the 3D expanded chondrocytes are 
re‐differentiated.
The system is comprised of two bioreactor units. The cartilage diges‐
tion bioreactor automates and controls the cartilage tissue digestion 
phase	Figure	2A,	and	the	T‐CUP perfusion bioreactor controls the cell 
seeding,	3D	proliferation	and	differentiation	phases	Figure	2B.	The	
digestion	bioreactor	and	T‐CUP	perfusion	bioreactor	were	installed	
within	 a	 declassified	 cleanroom	 at	 the	 GMP	 facility	 (Holostem	
Terapie	Avanzate;	declassified	to	permit	the	introduction	of	animal‐
derived	cells).	Laboratory	technicians	were	trained	for	autonomous	
use	 of	 the	 bioreactor	 systems	 as	well	 as	 all	 required	 cartilage	 tis‐
sue	engineering	bioprocesses.	In	line	with	GMP	guidelines,	a	proper	
quality	management	system	had	been	organized	 for	production	 in	
the	GMP	facility.	Stringent	records	ensured	full	traceability	of	all	ma‐
terials used. The complete manufacturing process was detailed and 
documented in standard operating procedures and manufacturing 
protocols.	Proper	quality	controls	were	established	to	ensure	stan‐
dardization	of	the	process	and	product.	Additional	testing	had	to	be	
performed on the starting materials prior entering the facility (eg 
mycoplasma	on	the	biopsy	at	arrival),	and	availability	of	GMP‐grade	
materials and reagents was verified for future clinical applications.
2.3 | Nasal cartilage biopsy
Prior to commencing the large animal studies, procedures for the 
handling,	packaging	and	transportation	of	biopsies	were	first	estab‐
lished,	tested	and	validated.	Additional	procedures	were	established	
to	facilitate	tracking	of	each	biopsy	as	well	as	a	documentation	sys‐
tem	 to	 streamline	 the	 delivery.	 Six	weeks	 prior	 to	 graft	 implanta‐
tion, a cartilage biopsy was harvested from the nasal septum of 
each	 sheep	with	 an	 8‐mm‐diameter	 biopsy	 punch.	 Perichondrium	
was scraped from the cartilage tissue with a scalpel, and biopsies 
were	thoroughly	washed	with	saline,	blotted	with	sterile	gauze	and	
stored	 in	 complete	medium	at	4°C	 for	 transport.	After	harvesting	
the	nasal	septum	cartilage	in	the	veterinary	clinic	in	Croatia,	biopsies	
were transported under defined conditions (eg overall duration of 
transport, temperature of transport vehicle, monitored temperature 
within	the	transport	container)	to	the	GMP	facility	in	Italy.	Animals	
were	kept	at	 the	clinic	post‐operatively	and	 then	 transported	 to	a	
family	farm	until	graft	implantation.	This	6‐week	time	period	allowed	
for the production of the nasal chondrocyte grafts.
2.4 | Cartilage tissue digestion
After	passing	defined	acceptance	criteria,	biopsies	were	cut	into	small	
pieces	(≈1‐2	mm)	and	transferred	into	the	digest	module	of	the	diges‐
tion	bioreactor.	The	digestion	bioreactor	 (Octane	Biotech)	 is	based	
upon	a	patient‐scale	cell	 therapy	system,	which	allows	automation	
of	cell	culture	processes	and	protocols	tailored	to	the	application.	A	
disposable	cassette	was	customized	for	this	study	protocol	and	com‐
posed	of	three	single‐use	modular	units:	 (a)	digest	module,	 (b)	fluid	
delivery	module	and	(c)	collection	module.	The	digest	module	houses	
the tissue biopsy and reagents during the process. The fluid deliv‐
ery module allows automated delivery of solutions (PBS, collagenase 
and	culture	medium)	through	the	digest	module	and	collection	mod‐
ule. The cell suspension is delivered automatically to the collection 
module at the end of the process. The digest bioreactor cassette is 
attached	 via	 non‐fluid	 contact	 to	 the	 bioreactor	 controller,	 which	
houses all the electronics, motor, valve actuators and software to 
control the system bioprocesses via the user interface. Biopsies were 
digested	with	0.15%	collagenase	type	II	in	complete	medium	(DMEM,	
10%	FBS,	0.1	mmol/L	non‐essential	amino	acids,	1	mmol/L	sodium	
pyruvate,	100	nmol/L	HEPES	buffer,	100	U/mL	penicillin,	100	µg/mL	
streptomycin	and	0.29	mg/mL	l‐glutamine)	within	the	automated	di‐
gestion	bioreactor	for	20	hours	at	37°C.	Isolated	chondrocytes	were	
harvested from the bioreactor collection module, counted and trans‐
ferred	to	the	T‐CUP	perfusion	bioreactor.
2.5 | Cell seeding, proliferation and differentiation
Nasal	 chondrocyte	 grafts	 were	 generated	 in	 the	 T‐CUP	 bioreac‐
tor	 using	 a	 streamlined	 bioreactor‐based	 process	 as	 previously	
described.6 Briefly, the limited number of primary chondrocytes, 
freshly isolated from the small cartilage biopsy, was seeded and ex‐
tensively expanded directly within the 3D scaffold in the bioreac‐
tor, therefore bypassing the conventional method of 2D expansion 
in	flasks.	The	T‐CUP	perfusion	bioreactor	system	(Cellec	Biotek	AG)	
is	composed	of	three	main	components:	(a)	vessel,	(b)	drive	unit	and	
(c)	 control	unit.	The	T‐CUP	vessel	houses	 the	scaffold	and	culture	
medium.	 Cells	 are	 seeded	 and	 cultured	 within	 the	 vessel.	 Sensor	
spots to measure the oxygen and pH of the culture medium are in‐
tegrated	within	the	vessel.	The	T‐CUP	drive	unit	controls	the	move‐
ment of the vessel which induces perfusion of culture media through 
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the	scaffold.	The	T‐CUP	control	unit	controls	the	drive	unit	via	the	
user interface. Inducing perfusion of cell suspension and/or culture 
medium	by	movement	of	the	scaffold	itself,	the	set‐up	and	all	associ‐
ated handling by the operator could be considerably simplified, with 
increased	product	safety	and	maximized	opportunities	for	upscaling.
Chondrocytes	were	seeded	into	the	bilayered	biomimetic	osteo‐
chondral	scaffold	25	mm	in	diameter	and	5	mm	in	thickness	under	al‐
ternating perfusion flow within the bioreactor at a perfusion rate of 
1	mm/second	for	16	hours	in	50	mL	of	complete	medium.	Following	
the	 perfusion	 cell	 seeding	 phase,	 cell‐seeded	 scaffolds	 remained	
within	the	bioreactor,	and	culture	medium	was	replaced	with	“pro‐
liferating	medium”	 (complete	medium	supplemented	with	1	ng/mL	
TGFβ1	and	5	ng/mL	FGF‐2)	to	expand	the	cells	directly	within	the	
scaffold.	Constructs	were	perfused	for	3	weeks	at	a	perfusion	rate	
of	100	µm/s	with	two	medium	exchanges	per	week.	Following	the	
3D	proliferation	phase,	 culture	medium	was	 replaced	with	 “differ‐
entiating	medium”	(complete	medium	supplemented	with	10	ng/mL	
TGFβ1,	1	IU/mL	insulin	and	0.1	mmol/L	ascorbic	acid	2‐phosphate)	
and constructs were cultured in the bioreactor for an additional 
2	weeks	with	medium	exchanges	three	times	per	week.	Throughout	
the proliferation and differentiation phases, pH and oxygen levels in 
the	medium	were	monitored	(measurements	acquired	every	10	min‐
utes)	with	chemo‐optic	sensors	(PreSens	GmbH)	integrated	into	the	
T‐CUP	bioreactor	vessel.	Following	5	weeks	of	production,	half	of	
each	engineered	nasal	chondrocyte‐based	graft	was	harvested	for	
histological assessments and the other half was transported from 
the	 GMP	 facility	 to	 the	 veterinary	 clinic	 using	 the	 transportation	
conditions and procedures established for biopsy transport.
2.6 | Acute defect model
The	 large	animal	 study	based	on	an	acute	defect	model	Figure	S1	
received	approval	from	local	research	ethics	committee	(University	
of	Zagreb,	Faculty	of	Veterinary	Medicine,	Class	640‐01/14‐17/49,	
Reg.	No.	251‐61‐01/139‐14‐4)	and	the	national	authorities	(Ministry	
of	 Agriculture	 of	 Croatia;	 Class	 UP/I‐322‐01/14‐01/84,	 Reg.	 No.	
525‐19/0255‐14‐4).	 Skeletally	 mature	 female	 German	 Wustenrot	
sheep,	between	the	ages	of	1	and	3	years	old	(57.2	±	13.7	kg),	were	
included in the studies. Sixteen animals were randomly assigned to 
two	experimental	groups:	cell‐based	grafts	manufactured	in	the	bio‐
reactor	(“BR,”	n	=	4	sheep	at	3M,	n	=	4	sheep	at	12M)	and	cell‐free	
scaffold	implants	(“CFS,”	n	=	4	sheep	at	3M,	n	=	4	sheep	at	12M).
2.7 | Chronic defect model
The	large	animal	study	based	on	a	chronic	defect	model	Figure	S1	
received	approval	from	local	research	ethics	committee	(University	
of	Zagreb,	Faculty	of	Veterinary	Medicine,	Class	640‐01/12‐17/99,	
Reg.	No.	251‐61‐01/139‐12‐2)	and	the	national	authorities	(Ministry	
of	 Agriculture	 of	 Croatia;	 Class	 UP/I‐322‐01/13‐01/79,	 Reg.	 No.	
525‐10/0255‐13‐3).	Nine	animals	(54.9	±	17.3	kg)	were	randomly	as‐
signed	to	two	experimental	groups	(BR	with	n	=	2	sheep	at	3M,	n	=	2	
sheep	at	12M;	and	CFS	with	n	=	2	sheep	at	3M,	n	=	3	sheep	at	12M).
• 1st joint surgery—defect creation:	Six	weeks	prior	to	graft	implan‐
tation, a cartilage biopsy was harvested from the nasal septum of 
each sheep as described above. In addition, cartilage defects were 
also created at this time on the load bearing surfaces of medial 
and	lateral	femoral	condyles	with	a	4‐mm‐diameter	biopsy	punch.	
Special	care	was	taken	not	to	damage	the	subchondral	bone.
• 2nd joint surgery—defect repair: Defects on the medial and lateral 
femoral	condyles,	which	had	chronified	over	the	6‐week	period,	
were converted to osteochondral defects 6 mm in diameter and 
5 mm in depth using a standard instrument for mosaicplasty 
(COR,	DePuy	Synthes).	Evidences	of	joint	inflammation	in	terms	of	
mild synovial oedema and hyperaemia were observed at the time 
of scaffold/tissue implantation in the chronic defect model. Prior 
to implantation, defects were washed with saline. Implantation of 
BR	grafts	and	CFS	implants,	post‐operative	care	and	harvesting	of	
the explants were similar as described in the acute defect model.
2.8 | Anaesthesia
For	 identification,	 ear	 tags	 were	 applied	 and	 microchips	 were	
placed	under	the	skin	at	the	back	of	the	neck	between	the	shoul‐
der	 blades	 on	 the	 dorsal	 midline.	 Animals	 had	 food	 removed	
24	 hours	 before	 surgery	 and	water	 removed	 8‐12	 hours	 ahead.	
Sheep were weighed and sedated with an intramuscular injection 
of	xylazine	0.1	mg/kg	(Xylapan,	Vetoquinol)	and	ketamine	7.5	mg/
kg	(Narketan,	Vetoquinol).	General	anaesthesia	was	induced	with	
an	injection	of	diazepam	0.2	mg/kg	(Apaurin,	Krka‐Farma	doo)	in	
the antebrachial vein, and if necessary, thiopental was also admin‐
istered	intravenously	at	a	dosage	of	5‐10	mg/kg.	An	endotracheal	
tube was placed in the trachea, and anaesthesia was maintained 
via	inhalational	of	a	mixture	of	1%‐2%	isoflurane	(Forane,	Abbott)	
and oxygen. Intraoperative analgesia was assured with continu‐
ous	administration	of	fentanyl	0.2	mg/kg/min	(Fentanyl	injections,	
Janssen	Pharmaceutica	NV).	Post‐operative	analgesia	was	assured	
with	 meloxicam	 15	 mg/1.5	 mL	 (Movalis,	 Boehringer	 Ingelheim,	
Croatia)	 in	 a	bolus	dose	of	0.2	mg/kg	 intramuscular	 followed	by	
a	dose	of	0.1	mg/kg	 intramuscular	once	a	day.	Antibiotic	proph‐
ylaxis	 was	 given	 via	 intravenous	 cefazolin	 20mg/kg	 (Zepilen,	
Medochemie/Medicuspharma).
2.9 | Graft implantation
Each stifle was physically examined for any abnormalities while 
anaesthetized.	The	animal	was	placed	in	a	dorsal	recumbence	po‐
sition, and following surgical preparation, the right stifle joint was 
opened via a medial parapatellar approach. The Hoffa was incised 
to	facilitate	visualization	of	the	joint,	and	the	knee	was	flexed	to	
make	 the	 medial	 femoral	 condyle	 visible.	 For	 the	 visualization	
and approach to the lateral femoral condyle, a lateral parapatel‐
lar	mini‐arthrotomy	was	 performed.	 After	 exposure,	 osteochon‐
dral defects measuring 6 mm in diameter and 5 mm in depth were 
created	with	a	standard	instrument	for	mosaicplasty	(COR,	DePuy	
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Synthes)	on	both	medial	 and	 lateral	 femoral	 condyles.	 In	 the	BR	
group, medial and lateral defects were both treated with autolo‐
gous	 nasal	 chondrocyte‐based	 grafts.	 In	 the	 CFS	 group,	 medial	
and	lateral	defects	were	both	treated	with	cell‐free	scaffolds.	BR	
grafts	and	CFS	implants	were	cut	to	a	cylindrical	shape	with	a	6‐
mm‐diameter	biopsy	punch	and	implanted	into	the	defects	using	
a	 press‐fit	 method.	 No	 additional	 fixation	 was	 used.	 After	 the	
implantation, the joint was cycled through a range of motion to 
ensure a satisfactory rim fixation of the implanted graft or scaf‐
fold, following which the joint was closed by standard surgical 
procedures.	 Post‐operatively,	 animals	 were	 allowed	 to	 bear	 full	
weight,	 but	 kept	 in	 small	 pens	 for	 5	 days	 to	 reduce	 ambulation.	
After	5	days	in	the	clinic,	animals	were	transferred	to	a	family	farm	
with no ambulation restrictions.
2.10 | Euthanasia and necropsy
Following	3	months	or	12	months,	animals	were	sedated	according	
to	anaesthesia	protocols	with	intramuscular	administration	of	keta‐
mine	and	xylazine	and	 subsequently	euthanized	with	 intravenous	
administration of T61. To harvest the treated defects, condyles 
were	cut	with	an	oscillation	saw.	From	each	condyle,	an	osteochon‐
dral	 tissue	 block	 containing	 the	 defect	 and	 surrounding	 cartilage	
was	cut	to	a	size	of	15	×	10	×	10	mm	and	subsequently	divided	into	
two halves.
2.11 | Explant characterization
2.11.1 | ICRS macroscopic scoring
Before explantation, two photographs of the exposed condyles were 
taken	in	situ.	After	explantation,	four	additional	photographs	were	
taken	of	each	condyle.	Three	blinded	orthopaedic	surgeons,	expe‐
rienced	 in	 using	 ICRS	macroscopic	 scoring	 system,	 independently	
scored the photographs.
2.11.2 | Histology and Immunohistochemistry
Osteochondral tissue samples for histology and immunohistochemi‐
cal	analysis	were	fixed	 in	4%	PFA,	decalcified	 in	15%	EDTA,	dehy‐
drated	 in	 ethyl	 alcohol	 and	 embedded	 in	 paraffin.	 Deparaffinized	
and	rehydrated	5‐µm	sections	were	stained	with	haematoxylin	and	
eosin	 (H&E),	 safranin‐O	and	picrosirius	 red.	 Slides	were	 examined	
under	a	bright	field	and	polarized	 light	microscope,	and	scored	ac‐
cording	to	ICRS	II	histology	criteria10 by two blinded and independ‐
ent	observers.	For	each	parameter,	nine	slides	were	examined	per	
explant	(three	slides	per	histological	stain)	to	determine	the	score.
For	the	immunohistochemical	detection	of	collagen	type	I,	col‐
lagen	type	II	and	aggrecan,	5‐µm	sections	were	deparaffinized	and	
rehydrated, and antigen retrieval performed by incubation with 0.1% 
proteinase	 K	 (Agilent	 Technologies),	 0.1%	 proteinase	 K	 and	 2.5%	
hyaluronidase,	 or	 0.2	 U/mL	 chondroitinase	 ABC	 (Sigma‐Aldrich),	
respectively. Sections were washed in PBS and endogenous per‐
oxidase	quenched	with	3%	H2O2.	Sections	were	then	blocked	with	
10%	goat	serum	and	incubated	with	anti‐collagen	I	 (1:100	dilution;	
#5D8‐G9,	Abcam),	anti‐collagen	II	antibody	(1:20	dilution;	#II‐II6B3,	
Developmental	Studies	Hybridoma	Bank),	anti‐aggrecan,	(1:50	dilu‐
tion;	#CSPG1,	Acris	Antibodies	GmbH)	or	an	isotype‐specific	immu‐
noglobulin	 at	 the	 corresponding	 concentration	 (negative	 control).	
Sections were washed in PBS and incubated with a secondary perox‐
idase‐conjugated	antibody	 (Dako	REAL	Envision	Detection	System	
kit,	Agilent	Technologies)	following	the	manufacturer's	instructions.	
Sections	 were	 incubated	 with	 3′,3′	 diaminobenzidine	 tetrahydro‐
chloride	(DAB)	and	counterstained	with	haematoxylin.	Normal	artic‐
ular cartilage and subchondral bone were used as positive controls.
2.11.3 | Histological quantification
To	quantify	immunohistochemical	staining	of	collagen	type	II,	slides	
were	 scanned	 with	 NanoZoomer	 2.0‐RS.	 The	 reference	 area	 was	
set to 32.5 mm2,	corresponding	to	the	size	of	the	defect.	Collagen	
F I G U R E  3   Explants from acute 
defects	treated	with	bioreactor	(BR)	
manufactured	grafts	and	cell‐free	scaffold	
(CFS)	implants.	Scale	bars	indicate	2	mm
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type	 II	 positive	 area	 was	 measured	 with	 NDPview2	 software.	
Quantification of immunohistochemical staining for collagen type I 
was	assessed	based	on	a	weighted	score.	First,	the	intensity	of	stain‐
ing	was	defined	with	grades	0‐5	(0	=	no	positive	staining,	1	=	very	
mild	positive	staining,	2	=	mild	positive	staining,	3	=	moderate	posi‐
tive	staining,	4	=	strong	positive	staining,	5	=	very	strong	positive	
staining).	 Slides	were	 scanned	with	NanoZoomer	 2.0‐RS,	 and	 the	
area	of	each	grade	was	measured	with	NDPview2	software.	Scores	
were calculated from the sum of each grade multiplied by its area. 
Immunohistochemical	 staining	 of	 aggrecan	 was	 quantified	 with	
scoring	grades	from	0	to	6	 (0	=	no	positive	staining,	1	=	very	mild	
positive	staining,	2	=	mild	positive	staining,	3	=	moderate	positive	
staining,	4	=	strong	positive	staining,	5	=	very	strong	positive	stain‐
ing	as	in	normal	cartilage,	6	=	very	strong	staining	that	extends	out‐
side	the	cartilage	layer	into	subchondral	bone).
2.12 | Statistics
Quantitative	 data	 are	 expressed	 as	 the	mean	 ±	 standard	 devia‐
tion	(SD).	To	analyse	differences,	independent‐samples	t test was 
F I G U R E  4   ICRS	II	histology	scores	of	explants	from	acute	defects	treated	with	bioreactor	(BR)	manufactured	grafts	and	cell‐free	
scaffold	(CFS)	implants.	A,	3‐mo	explants.	B,	12‐mo	explants.	Data	are	presented	as	mean	+	SD.	(*indicates	statistically	significant	difference	
between	BR	and	CFS)
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used	 and	Hedges	 g	 effect	 size	was	 calculated	using	 the	 formula	
from Ellis, P.D. 11	 Welch‐Satterthwaite	 correction	 was	 used	 for	
variables	with	unequal	variances	between	groups,	as	determined	
by	 Levene's	 test.	 Due	 to	 the	 number	 of	 comparisons	 in	 ICRS	 II	
histology	scores,	the	Benjamini‐Hochberg	procedure	was	used	to	
control for false discovery rates12 to determine statistical signifi‐
cance.	For	other	tests,	P values >0.05 were considered statistically 
significant.	All	analyses	were	performed	with	IBM	SPSS	Statistics	
(version	22.0.	Armonk,	IBM	Corp).
3  | RESULTS
3.1 | Bioreactor‐based manufacture
All	of	 the	bioreactor‐based	production	 runs,	 for	both	animal	 stud‐
ies, were successfully completed. Digestion of nasal cartilage bi‐
opsies in the automated digestion bioreactor provided a yield of 
28,400	 ±	 19,100	 nasal	 chondrocytes	 per	 biopsy.	 Preliminary	 ex‐
periments showed that nasal chondrocytes were seeded predomi‐
nantly within the chondral region of the bilayered scaffold (data not 
shown).	Therefore,	scaffolds	were	seeded	at	an	average	density	of	
2.9E	 +	 04	 chondrocytes/cm3 scaffold volume (accounting for the 
volume	of	the	chondral	layer	only).	Oxygen	measurements	acquired	
throughout the production process showed a large drop in the oxy‐
gen	level	over	2	to	3	weeks	of	the	3D	proliferation	phase	(Figure	2C,	
100%	air	 saturation	 corresponding	 to	21%	oxygen	 concentration).	
Oxygen	levels	then	reached	a	plateau	of	10%‐30%	air	saturation	lev‐
els	during	the	2‐week	differentiation	phase.	pH	profiles	were	con‐
sistent with oxygen profiles, showing a large drop in pH over the 3D 
proliferation	phase	Figure	2D.	Since	culture	medium	was	exchanged	
batchwise, large pH fluctuations can be observed between the intro‐
duction	of	fresh	medium	(pH	≈	7.6)	until	the	next	medium	exchange	
(pH	≈	6.8‐7.0).
Following	5	weeks	of	production,	 engineered	grafts	 contained	
extracellular matrix that loosely filled the pores of the chondral 
layer	of	the	scaffold.	Although	some	cells	could	be	observed	within	
the bone layer of the scaffold, cells were predominately distributed 
within	the	chondral	layer	Figure	S2,	since	the	chondral	layer	of	the	
scaffold is structurally more favourable to cell invasion, while the 
more	compact	mineralized	layer	is	rather	cell‐occlusive.
3.2 | Acute defect model
Grafts	produced	in	the	established	bioreactor‐based	manufacturing	
system were first tested in an acute defect model, based on freshly 
created osteochondral defects. Surgical wounds healed well after 
arthrotomy, with no signs of oedema, inflammation or wound de‐
hiscence.	Upon	 explantation,	 there	were	 no	 signs	 of	 delamination	
or	dislocation	of	any	grafts	or	implants.	Unfortunately,	three	sheep	
in	the	BR	group	died	(two	in	the	3‐month	group	and	one	in	the	12‐
month	group).	Upon	examinations	by	an	independent	examiner,	rea‐
sons of death were found to be unrelated to the surgical procedures 
or to the implants.
3.2.1 | Macroscopic evaluation
At	 3	months,	 BR	 explants	 had	 better	 gross	morphology	 than	CFS	
explants	Figure	3,	with	significantly	higher	ICRS	overall	macroscopic	
scores	(BR:	7.3	±	0.82,	n	=	4	vs	CFS:	2.8	±	1.5,	n	=	8;	P	=	0.0002).	
BR	defects	were	filled	with	glossy	white	tissue,	while	CFS	defects	
were	partially	filled	with	granulation/fibrous	tissues.	At	12	months,	
cartilage repair appeared macroscopically better for both groups 
compared	to	the	3‐month	time	point.	Repair	tissue	filled	the	defects	
and appeared to be integrated with the surrounding cartilage for 
both groups. The surface of BR defects appeared smoother with less 
fissures	and	had	significantly	higher	 ICRS	macroscopic	scores	 (BR:	
9.1	±	0.8,	n	=	6;	vs	CFS:	6.8	±	1.9,	n	=	8;	P	=	0.014)	as	compared	to	
CFS	defects.
3.2.2 | Histological evaluation
At	 3	 months,	 ICRS	 II	 histological	 scores	 were	 significantly	 higher	
for	 BR‐treated	 defects	 than	 CFS	 for	 the	 parameters:	 tissue	 mor‐
phology (P	 =	 0.037),	 matrix	 staining	 (P	 =	 0.008),	 surface	 archi‐
tecture (P	 =	 0.013),	 basal	 integration	 (P	 =	 0.023),	 subchondral	
bone (P	 =	 0.049),	 vascularization	 (P	 =	 0.019),	 surface	morphology	
(P	=	0.012),	deep	zone	morphology	(P	=	0.024)	and	the	overall	score	
(P	=	0.001)	Figure	4A.	BR‐treated	defects	were	 filled	with	hyaline	
cartilage,	 positively	 stained	 for	 safranin‐O	 and	 collagen	 type	 II	
Figure	3,	as	well	as	aggrecan.	Chondrocytes	were	embedded	within	
lacunae,	although	with	a	random	organization.	Cartilaginous	repair	
tissue in BR defects appeared to be integrated with the surrounding 
native	cartilage.	CFS‐treated	defects	were	only	partially	filled	with	
granulation	and	 fibrous	 tissues	 that	 stained	poorly	 for	 safranin‐O,	
collagen type II and aggrecan. The partial filling resulted in cavities at 
the	centre	of	these	defects.	CFS	defects	contained	abundant	blood	
vessels, as well as leucocytes and macrophages, consistent with 
wound healing and tissue remodelling. Residual scaffold material 
was	detected	in	the	defects	of	CFS	explants	Figure	S3.	In	contrast	to	
BR	defects,	cartilage‐cartilage	integration	was	not	observed	for	the	
CFS	group.	Although	no	tidemark	could	be	observed	at	3	months	for	
either group, subchondral bone regeneration was more advanced in 
BR	defects	than	in	CFS.	Repair	tissue	in	BR	defects	was	integrated	
with surrounding bone and contained areas of active ossification. 
In	 contrast,	 the	 subchondral	 region	 in	 CFS	 defects	 was	 only	 par‐
tially filled with loose granulation tissue, with few areas of active 
ossification.
The	quantified	area	of	collagen	type	II	staining	was	significantly	
larger	 for	 BR	 vs	 CFS	 in	 the	 chondral	 region	 of	 the	 repair	 tissues	
(3.5	±	1.2	vs	1.6	±	0.71	mm2; P	=	0.006).	Although	histological	scoring	
of	aggrecan	staining	was	higher	for	BR	vs	CFS	in	the	chondral	region	
(3.0	±	2.21	vs	0.9	±	1.68;	P	=	0.098),	the	difference	was	not	statis‐
tically significant. The scoring of collagen type I staining was similar 
for	BR	and	CFS	in	the	chondral	region	(0.25	±	0.21	and	0.44	±	0.35)	
as	well	as	in	the	subchondral	region	(1.75	±	0.76	and	2.49	±	1.27).
At	12	months,	there	were	no	significant	differences	in	the	ICRS	
II	histological	scores	between	the	BR	and	CFS	explants	Figure	4B.	
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However, nearly all scores were higher at 12 months compared to 
the	 3‐month	 time	 point.	 BR	 and	CFS	 defects	were	 filled	with	 hy‐
aline	matrix,	positively	stained	for	safranin‐O,	collagen	type	 II	and	
aggrecan,	and	a	columnar	organization	of	chondrocytes.	While	the	
safranin‐O‐stained	area	appears	 larger	throughout	3‐month	BR	ex‐
plants than throughout	 12‐month	BR	 explants	 Figure	 3,	 the	 chon‐
dral region was assessed separately from the subchondral region for 
histological	quantifications	as	well	as	for	specific	parameters	of	the	
ICRS	II	histological	scores.	Virtually,	no	collagen	type	I	staining	was	
observed	in	the	chondral	layer	of	either	BR	or	CFS	groups.	The	repair	
tissue in both groups had a smooth surface and appeared integrated 
with the surrounding cartilage tissue, with no discernible borders. 
Hyaline cartilage extended into the subchondral region of the BR 
group,	whereas	collagen	type	I	with	a	bone‐like	structure	filled	the	
subchondral	region	of	the	CFS	group.	Large	areas	of	cystic	fibrous	
tissue	were	present	in	the	subchondral	bone	of	the	CFS	group	Figure	
S4.	The	presence	of	pseudocysts	was	observed	in	the	subchondral	
region	of	both	BR	and	CFS	defects.
The	 quantified	 area	 of	 collagen	 type	 II	 staining	 (3.8	 ±	 1.1	 vs	
3.8	 ±	 0.97	mm2)	 and	 the	 histological	 scoring	 of	 aggrecan	 staining	
(2.3	±	1.2	 and	2.7	±	1.5)	were	 similar	 for	BR	 vs	CFS	 in	 the	 chon‐
dral	 region	of	 the	 repair	 tissues	 at	 12	months.	Negligible	 collagen	
type I staining was observed in the chondral region of either group. 
Collagen	I	scoring	of	the	subchondral	region	was	significantly	lower	
for	BR	vs	CFS	(2.5	±	0.93	vs	4.1	±	0.86,	P	=	0.005).
3.3 | Chronic defects
Following	the	promising	results	obtained	with	bioreactor‐produced	
engineered grafts in the acute defect model, we next aimed to as‐
sess the grafts in a more challenging and more clinically relevant 
model of a chronic defect.
F I G U R E  5   Explants from chronic 
defects	treated	with	bioreactor	(BR)	
manufactured	grafts	and	cell‐free	
scaffold	(CFS)	implants.	A,	Macroscopic	
and histological assessments after 3 
and 12 mo. Scale bar indicates 2 mm. 
B‐G,	12‐mo	explants	from	chronic	
defects.	B,	C,	In	BR	chronic	defects,	we	
observed restoration of articular cartilage 
with	chondrocytes	(arrows)	in	zonal	
organization	typical	for	articular	cartilage.	
E,	F,	CFS	defects	healed	with	fibrous	
tissue mixed with hyaline cartilage. Both 
chondrocytes	(arrows)	and	connective	
tissue	cells	(arrowheads)	are	present,	
but	with	no	tissue	organization.	D	and	
G	Picrosirius‐stained	images	observed	
under	polarized	light	microscope	show	
excellent	cartilage‐to‐cartilage	integration	
in BR explants, with homogenous fibril 
organization	across	the	defect.	Poor	
cartilage	healing	is	observed	in	CFS	
explants,	with	thick	non‐organized	fibres.	
B,	C,	E,	F,	Safranin‐O	staining.	D,	G,	
Picrosirius red staining as observed under 
polarized	light	microscopy.	Scale	bar	
indicates	100	µm
(A)
(B)
(E)
(C) (D)
(F) (G)
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3.3.1 | Macroscopic evaluation
At	3	months,	BR	and	CFS	defects	were	partially	filled	with	hyaline	
and	fibrous	tissues	Figure	5A ,	with	similar	ICRS	macroscopic	scores	
(BR:	4.2	±	2.0,	n	=	4	and	CFS:	4.8	±	1.2,	n	=	4).	One	of	the	BR	defects	
was nearly completely filled. Tissue formed in the defects of both BR 
and	CFS	appeared	 to	be	 integrated	with	 the	surrounding	cartilage	
but	areas	with	demarcation	borders	were	noticeable.	At	12	months,	
cartilage repair appeared better for both groups compared to the 
3‐month	time	point.	Unfortunately,	due	to	reasons	unrelated	to	the	
surgery or to the implants, only one sheep in the BR group survived 
the full 12 months, and therefore, no statistical analyses were per‐
formed	for	the	12‐month	time	point.	Nevertheless,	for	the	two	BR	
defects	 assessed,	 ICRS	 macroscopic	 scores	 were	 higher	 than	 for	
any	of	the	six	CFS	defects	(BR:	10.7	±	0.6,	n	=	2;	vs	CFS:	5.5	±	2.01,	
n	=	6).	BR	defects	were	completely	filled	with	glossy	white	hyaline‐
like	tissue,	with	a	smooth	surface	and	which	was	integrated	with	the	
surrounding	 cartilage	 tissue.	 In	 contrast,	 CFS	 explants	 contained	
F I G U R E  6   ICRS	II	histology	scores	of	explants	from	chronic	defects	treated	with	bioreactor	(BR)	manufactured	grafts	and	cell‐free	
scaffold	(CFS)	implants.	A,	3‐mo	explants.	B,	12‐mo	explants.	Data	are	presented	as	mean	+	SD.	(*indicates	statistically	significant	difference	
between	BR	and	CFS)
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fibrous tissue only partially filling the defect, with visible fissures 
and uneven edges.
3.3.2 | Histological evaluation
At	3	months,	ICRS	II	histological	scores	were	significantly	higher	for	
BR‐treated	defects	than	for	CFS	defects	for	the	parameters:	tissue	
morphology (P	=	0.0079),	matrix	staining	(0.0247),	cell	morphology	
(P	 =	 0.0066),	 surface	 architecture	 (P	 =	 0.0067),	 basal	 integration	
(P	 =	 0.0035),	 inflammation	 (P	 =	 0.0357),	 vascularization	 (0.0023),	
surface morphology (P	=	0.129),	deep	zone	assessment	(P	=	0.0078)	
and overall score (P	=	0.0015)	Figure	6A.	BR‐treated	defects	were	
filled	 with	 hyaline	 cartilage,	 positively	 stained	 for	 safranin‐O	 and	
collagen	type	II	Figure	5A,	as	well	as	aggrecan.	Cartilaginous	repair	
tissue in BR defects appeared to be integrated with the surrounding 
native	cartilage.	CFS	defects	were	 infiltrated	with	abundant	blood	
vessels and were only partially filled with granulation and fibrous 
tissues	that	stained	poorly	 for	safranin‐O,	collagen	type	 II	and	ag‐
grecan. The partial filling resulted in cavities at the centre of the 
defects,	with	safranin‐O	staining	of	CFS	explants	predominately	lo‐
calized	near	the	border	region	of	the	repair	tissue	and	surrounding	
native	cartilage.	Cartilage‐cartilage	integration	was	not	observed	in	
the	CFS	explants,	having	a	clear	border	and	demarcated	transition	
between	the	repair	tissue	and	surrounding	native	cartilage.	As	in	the	
acute defect model, residual scaffold material was observed in the 
CFS	group	Figure	S3.	Repair	tissue	in	the	subchondral	bone	region	
of BR explants had visible areas of ossification and appeared to be 
integrated	 to	 surrounding	native	bone.	 In	CFS	explants,	 repair	 tis‐
sue in the subchondral bone region was predominately hypervascu‐
lar and loose granulation tissue with only few areas of ossification. 
Macrophages	and	leucocytes	were	present	in	both	groups	but	much	
more	prevalent	in	CFS	explants.
The	 quantified	 area	 of	 collagen	 type	 II	 staining	 (3.3	 ±	 1.6	 vs	
3.2	 ±	 1.8	 mm2)	 and	 the	 histological	 scoring	 of	 aggrecan	 staining	
(1.2	 ±	 0.8	 vs	 1.0	 ±	 1.7)	were	 similar	 for	BR	 and	CFS	 in	 the	 chon‐
dral region of the repair tissues. Weighted scoring of collagen type I 
staining	was	similar	for	BR	and	CFS	in	both	the	chondral	(0.1	±	1.3	vs	
0.4	±	0.3)	and	subchondral	(1.8	±	1.0	vs	3.0	±	1.0)	regions.
At	12	months,	defect	repair	in	both	the	BR	and	CFS	groups	had	
improved	 compared	 to	 the	 3‐month	 time	 point.	 For	 the	 two	BR	
defects	assessed,	ICRS	II	histological	scores	were	higher	than	for	
the	six	CFS	defects	for	the	parameters:	tissue	morphology,	matrix	
staining, cell morphology, chondrocyte clustering, surface archi‐
tecture,	tidemark	formation,	surface,	deep	zone	and	overall	score	
Figure	6B.	The	chondral	 layer	of	BR	defects	was	comprised	of	a	
smooth	 layer	of	hyaline‐like	cartilage,	positively	stained	for	safr‐
anin‐O,	collagen	type	II	and	aggrecan.	Interestingly,	chondrocytes	
were	embedded	within	lacunae	organized	in	a	columnar	distribu‐
tion	 resembling	 native	 cartilage	 Figure	 5B,	 5.	 The	 articular	 sur‐
face was completely covered with a continuous hyaline cartilage 
layer, with no discernible border between the repair tissue and the 
surrounding	 native	 cartilage	 Figure	 5D.	 Repair	 tissue	within	 the	
chondral	region	of	CFS	defects	was	comprised	primarily	of	fibrous	
tissue	Figure	5E,	5.	Fibrocartilage	was	present	only	near	the	de‐
fect	 edges,	 which	 only	 faintly	 stained	 for	 safranin‐O,	 collagen	
type II and aggrecan. In addition, blood vessels were observed in 
the	chondral	region	of	all	CFS	defects.	Upward	migration	of	sub‐
chondral plate was observed in BR explants as well as the forma‐
tion	of	the	tidemark	between	the	cartilage	and	subchondral	bone	
regions.	In	contrast,	subchondral	bone	in	CFS	defects	regenerated	
circumferentially with fibrous tissue present in the central sub‐
chondral	region.	Moreover,	cysts	were	present	in	the	subchondral	
region	of	most	CFS	explants.
The	quantified	area	of	collagen	type	II	staining	(3.4	vs	2.3	mm2)	
and	scoring	of	aggrecan	staining	(4.5	±	0.4	vs	0.4	±	0.5)	were	larger	
for	BR	vs	CFS	in	the	chondral	region	at	12	months.	Weighted	scor‐
ing	of	collagen	type	I	was	similar	for	BR	and	CFS	in	both	the	chon‐
dral	(0.0	±	0.0	vs	0.3	±	0.6)	and	subchondral	(4.7	±	0.5	vs	4.0	±	0.9)	
regions.
4  | DISCUSSION
In	this	work,	we	have	established	a	bioreactor‐based	manufacturing	
system	for	the	production	of	chondrocyte‐based	engineered	grafts.	
All	 bioreactor	 technologies	 and	 cartilage	 tissue	 engineering	 bio‐
processes	were	transferred	to	an	independent	GMP	facility	where	
all engineered grafts were successfully manufactured for two large 
animal studies. The results of these studies demonstrate the safety 
and	 feasibility	 of	 the	 bioreactor‐based	 manufacturing	 approach.	
Moreover,	grafts	produced	in	the	bioreactor	manufacturing	system	
were first shown to accelerate the repair of acute osteochondral 
defects	 compared	 to	 cell‐free	 scaffold	 implants.	We	 then	demon‐
strated that grafts produced in the system also resulted in a faster 
repair in a more clinically relevant chronic defect model. The data 
also	suggest	that	the	bioreactor‐manufactured	grafts	may	result	in	a	
more robust repair at a longer term point.
We have previously established a number of bioreactor tech‐
nologies3‐5 that have served as the foundation to establish a man‐
ufacturing process for the production of engineered tissue grafts in 
this	study.	Using	this	manufacturing	platform,	we	have	implemented	
an innovative streamlined process to expand the limited number of 
primary chondrocytes, which can be isolated from a small cartilage 
biopsy, directly within a porous 3D scaffold, bypassing the conven‐
tional	manual	process	of	cell	expansion	in	tissue	culture	flasks.6	Using	
this process, cell seeding, 3D expansion and differentiation were all 
performed within a single perfusion bioreactor manufacturing mod‐
ule. In addition, digestion of the cartilage biopsy and preparation of 
the isolated cell suspension were performed in an innovative auto‐
mated cartilage digestion bioreactor module. Therefore, all biopro‐
cesses, from the introduction of the cartilage biopsy through the 
generation of the engineered graft, were performed in our biore‐
actor‐based	manufacturing	 system.	By	minimizing	 labour‐intensive	
operator‐dependent	procedures	and	controlling	the	manufacturing	
processes,	 our	 bioreactor	 system	 has	 the	 potential	 to	 (a)	 improve	
standardization	 of	 the	 manufacturing	 process	 and	 reproducibility	
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of	product	quality,	 (b)	 increase	safety	of	 the	process	and	product,	
(c)	 facilitate	 significant	 scaling	of	 production	volumes,	 (d)	 increase	
the	 cost‐effectiveness	 of	 the	 engineered	 product	 and	 (e)	 simplify	
transferability of the production to other manufacturing centres.13 
In	addition,	non‐invasive	sensors	were	integrated	into	the	bioreactor	
system to monitor oxygen and pH levels throughout the manufac‐
turing process. Sensing and online monitoring offer great advan‐
tages	to	provide	non‐invasive	and	quantitative	data	relevant	to	the	
process	and	the	engineered	graft,	providing	meaningful	 in‐process	
quality	controls	and	data	on	graft	quality.	Automated	logging	of	our	
sensor	data	along	with	other	key	process	parameters	will	 increase	
traceability of the process and will therefore facilitate compliance to 
strict regulatory guidelines. The integrated sensors could be used in 
the future not only to monitor, but also to maintain pH and oxygen 
at	predefined	levels	in	a	feedback	controlled	loop.	This	may	not	only	
improve	and	 standardize	graft	quality,	but	would	considerably	 im‐
prove	process	robustness	and	standardization	for	reduced	process	
and product variability.
One potential limitation of our manufacturing strategy was the 
approach	of	utilizing	a	centralized	manufacturing	facility	for	the	pro‐
duction of the engineered grafts. This approach imposes significant 
logistical and regulatory challenges, as well as high costs, simply for 
the transportation of biopsies and grafts between the central facility 
and	the	clinical	 site.	On	the	other	hand,	a	centralized	manufactur‐
ing facility allows for highly trained operators to closely oversee the 
manufacturing	 process,	 to	 conduct	 in‐process	 controls	 and	 to	 re‐
lease	the	final	engineered	product	in	accordance	with	well‐defined	
quality	control	release	criteria.	As	specific	assays	will	be	required	to	
characterize	the	final	engineered	product,	it	may	be	challenging	and	
cost	prohibitive	for	a	de‐centralized	facility	to	have	available	a	quali‐
fied	laboratory	with	qualified	instruments,	validated	procedures	and	
the	 trained	operators	 that	would	be	 required	 to	perform	 the	nec‐
essary assays. In the future, it may be possible to establish a sim‐
ple	to	use	plug‐and‐play	bioreactor	system	which	could	be	installed	
into	 qualified	 clinical	 centres	 for	 the	 de‐centralized	 production	 of	
engineered tissues, mitigating complex logistical issues as well as 
automating	aspects	of	quality	control.	Nevertheless,	this	will	still	re‐
quire	substantial	expertise	and	 investment	 in	 infrastructure	at	 the	
production sites.
Engineered grafts produced in the manufacturing system were 
first	assessed	 in	a	well‐established	 large	animal	model	of	cartilage	
repair, based on freshly created osteochondral defects.14	At	the	early	
observational time point of 3 months, grafts generated in the biore‐
actor	 system	 resulted	 in	 a	 better	 repair	 than	 cell‐free	 implants	 as	
assessed	by	ICRS	macroscopic	criteria	and	by	9	out	of	the	14	param‐
eters	of	the	ICRS	II	histological	scoring	criteria.	Histological	images	
of the best, the intermediate and the worst repair for each treatment 
group	in	the	acute	model	are	shown	in	Figure	S5.	BR‐treated	defects	
were filled with glossy white hyaline cartilage tissue that appeared 
integrated with the surrounding native cartilage tissue along with 
more advanced subchondral bone regeneration. While we observed 
hyaline cartilage tissue also within the subchondral bone layer of BR 
defects	at	both	3	and	12	months,	it	is	likely	that	this	cartilage	tissue	
would ultimately remodel into bone if assessed at later time points. 
Designed	 for	 human	 applications,	 the	 thickness	 of	 the	 implanted	
graft	cartilage	exceeded	the	thickness	of	articular	cartilage	in	sheep	
stifle	 joint,	which	varies	between	0.4	and	0.5	mm.15	More	precise	
scaffold	design	to	better	fit	cartilage	thickness	of	the	experimental	
animal may favour development of stable cartilage in the chondral 
layer	only.	Although	differences	were	not	detected	histologically	be‐
tween	the	groups	later	at	the	12‐month	time	point,	clinical	observa‐
tions	by	the	orthopaedic	surgeons	(ICRS	macroscopic	scores)	would	
suggest	more	 advanced	 defect	 healing	 in	 the	 BR‐treated	 defects.	
Taken	 together,	 the	extent	of	 repair	observed	at	both	 time	points	
in the acute defect model indicates great promise for the bioreac‐
tor‐generated	grafts.	In	particular,	more	advanced	repair	at	an	early	
time point could have great implications on the clinical and commer‐
cial	success	of	an	engineered	tissue	graft.	An	accelerated	repair	may	
allow	earlier	post‐operative	joint	 loading	and	shorter	rehabilitation	
times, with a more rapid return of the patient to normal life activities. 
This	would	have	a	significant	benefit	in	terms	of	both	quality	of	life	
and reduction of healthcare costs, with the potential to influence 
claim reimbursement by health insurances and/or social systems.
Based on the promising results from the acute defect model, 
we	next	aimed	to	assess	the	bioreactor‐generated	grafts	in	a	more	
challenging model of a chronic defect. While the acute defect model 
(treatment	of	freshly	created	defects)	has	been	long	established	for	
studying cartilage repair strategies, a patient would rarely be treated 
in the clinic immediately following an injury to their cartilage tis‐
sue. Therefore, to better mimic a clinical scenario, we have imple‐
mented a chronic defect model, in which defects were first created 
on	 the	weight‐bearing	 surfaces	of	 the	 sheep	 condyle	 and	 allowed	
to	chronify	over	a	6‐week	period	prior	to	treatment	with	grafts	and	
implants.16
Despite the highly challenging model, all chronic defects were 
partially filled with repair tissue at 3 months. While both treatment 
groups had similar gross appearances, chronic defects treated with 
bioreactor‐generated	 grafts	 resulted	 in	 a	 better	 repair	 based	 on	
10	out	of	14	parameters	of	the	ICRS	II	histological	scoring	criteria.	
Histological images of the best, the intermediate and the worst re‐
pair for each treatment group in the chronic model are shown in 
Figure	S6.	BR‐treated	defects	were	filled	with	hyaline	cartilage	that	
appeared integrated with the surrounding native cartilage and an 
ossifying subchondral region integrated with the surrounding native 
bone.	While	CFS	defects	remained	only	partially	filled	with	fibrous	
tissue	 following	12	months,	 bioreactor‐treated	defects	were	 com‐
pleted	filled	with	a	smooth	layer	of	glossy	white	hyaline‐like	tissue.	
Interestingly, while chondrocytes were found randomly distributed 
in the chondral repair tissue at the early time point, at 12 months, 
cells	were	embedded	within	lacunae	and	organized	in	structures	re‐
sembling that of native articular cartilage. While cartilage extended 
into	the	subchondral	bone	with	no	evident	tidemark	at	3‐month	time	
point, at 12 months, cartilage was present in the chondral region 
only—separated from the subchondral region by a discernible tide‐
mark.	Moreover,	while	cartilage‐cartilage	integration	remains	a	key	
challenge to address in cartilage repair strategies, at 12 months, in 
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both	the	acute	and	chronic	models,	the	repair	tissues	in	bioreactor‐
treated defects appeared well integrated with the surrounding na‐
tive	tissues,	with	no	detectable	borders.	Finally,	subchondral	bone	
remodelling appeared nearly complete, including the formation of a 
discernible	tidemark	between	the	chondral	and	subchondral	regions.	
As	opposed	to	the	acute	defect	model,	there	was	no	persistence	of	
cartilage tissue within the subchondral bone layer of the BR defect. 
As	 reported	 in	 the	 literature,	 it	 is	 possible	 that	 the	 inflammatory	
environment in the chronic defect has facilitated the conversion of 
cartilage into bone.17
The	results	of	the	chronic	model	are	quite	impressive	considering	
the mechanical loading and inflammatory conditions that the grafts 
were	subjected	to.	Since	sheep	were	not	 immobilized	after	surgery,	
the	animals	 could	walk	 freely	post‐operatively.	Our	data	 show	 that	
BR grafts, which were implanted into high load bearing regions of the 
condyle and therefore subjected to mechanical loading soon after 
implantation, resulted in hyaline repair tissue resembling native carti‐
lage tissue. This supports a previous in vitro study showing that nasal 
chondrocytes can respond positively to physical forces resembling 
joint loading, increasing the production of cartilaginous extracellu‐
lar matrix proteins.18 Our results are also consistent with another in 
vitro study showing that nasal chondrocytes have a high capacity to 
recover from inflammatory conditions, suggesting that nasal chondro‐
cyte‐based	grafts	could	have	more	favourable	chances	to	successfully	
engraft into the joint and regenerate the articular cartilage surface.19
While the level of maturation of engineered cartilage grafts, 
perhaps enhanced by bioreactor mechanical preconditioning, could 
potentially affect in vivo integration and remodelling, this hypothe‐
sis	was	outside	the	scope	of	this	work.	However,	we	are	currently	
addressing	this	question	in	an	ongoing	multicentre	phase	II	clinical	
study by comparing the clinical efficacy of mature vs immature tis‐
sue engineered grafts for the treatment of traumatic cartilage le‐
sions	 in	 the	 knee	 (Nose	 to	 Knee	 II,	 Swissmedic	 2016‐TpP‐2004).	
Nevertheless,	 in	 this	current	manuscript	we	describe	that	 the	bio‐
reactor‐generated	 grafts	 could	 be	 safely	 implanted	 into	 high	 load	
bearing sites, subjected to mechanical loading soon after implanta‐
tion, and result in hyaline repair tissue resembling native cartilage. If 
engineered cartilage grafts can be generated with sufficient proper‐
ties	to	meet	defined	quality	criteria	without	the	use	of	mechanical	
preconditioning,	bioreactor	automation	requirements	can	be	greatly	
simplified, thereby facilitating the development of a more compact, 
user‐friendly	 and	 cost‐effective	 bioreactor‐based	 manufacturing	
system—facilitating clinical translation.
5  | CONCLUSION
Conventional	manufacturing	strategies	present	significant	hurdles	
for	the	cost‐effective	translation	of	cell‐based	engineered	grafts	to	
the clinic. By demonstrating safety of the generated grafts in two 
large	animal	models,	 this	work	represents	a	pivotal	step	towards	
a	 regulatory	 compliant,	 bioreactor‐based	 clinical	 manufacturing	
strategy	 for	 human	 engineered	 cartilage	 implants.	 Moreover,	 in	
view of the significant challenges typically associated with treat‐
ing advanced cartilage defects, the promising efficacy results of 
our approach in a chronic defect model highlight its potential ap‐
plicability not only for the treatment of small focal cartilage le‐
sions, but also for a broader range of clinical indications. Ongoing 
efforts	 are	 currently	 aimed	at	qualifying	 the	bioreactor	 technol‐
ogy and validating the associated bioprocesses in preparation for 
a	first‐in‐human	clinical	study.
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